**Anti-cardiolipin (aCL) IgG and IgM antibodies** are autoantibodies—immune proteins that mistakenly target the body's own cell membranes, specifically phospholipids.
Testing for both types is essential when evaluating unexplained blood clots, recurrent miscarriages, or autoimmune diseases like systemic lupus erythematosus (SLE). **IgM** antibodies usually appear first during an initial immune response, while **IgG** antibodies develop later and typically persist longer, often carrying a stronger clinical association with clotting risks.
Elevated levels of either antibody serve as primary diagnostic markers for **Antiphospholipid Syndrome (APS)**, a condition requiring careful medical management to prevent future thrombotic events.

The **Anti-CCP (Anti-Cyclic Citrullinated Peptide) test** is a highly specific blood test used primarily to diagnose **Rheumatoid Arthritis (RA)**. It detects autoantibodies that mistakenly target citrullinated proteins, which are formed during joint inflammation.
With a specificity of over 95%, a positive result strongly indicates RA, helping physicians differentiate it from other forms of arthritis early in the disease course. Furthermore, elevated anti-CCP levels are strong prognostic indicators, often predicting a more aggressive, erosive form of joint damage. Early detection via this panel allows for timely therapeutic intervention, significantly improving long-term joint outcomes.